Case Report: Dacomitinib May Not Benefit Patients Who Develop Rare Compound Mutations After Later-Line Osimertinib Treatment

• DOI: 10.3389/fonc.2021.649843
• Publication Date: 2021-04-15T15:45:07Z
• Authors: Hong-Shuai Li; Guang-Jian Yang; Yan Wang
• Keywords: Osimertinib; T790M; Acquired resistance

The acquired EGFR C797X mutation has been identified as the most notable resistance to osimertinib, and novel secondary mutations of L718 L792 residues have also demonstrated confer osimertinib resistance, making choice medication after treatment a quandary. Dacomitinib reported potential impact on patients acquiring rare compound resistance; however, little evidence is available date. In five lung adenocarcinoma resistant later-line recurrent at and/or were using targeted next-generation sequencing tissue or cell-free DNA from plasma pleural effusion. was initiated all progressed within 2 months. Molecular structural simulation revealed that L792H + T790M L718Q could interfere with binding dacomitinib potentially cause primary drug resistance. Our case series study, our knowledge, first report clinical efficacy in harboring complex